Who are APL-130277's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Neupro, DC, Rotigotine transdermal patch, ROP+L-Dopa, DAM, amantadine sulfate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apl-130277.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

APL-130277 — Competitive Intelligence Brief

APL-130277 (APL-130277) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine agonist. Area: Neurology.

phase 3 Dopamine agonist Dopamine receptors (D1, D2) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

APL-130277 (APL-130277) — Sumitomo Pharma America, Inc.. APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
APL-130277 TARGET	APL-130277	Sumitomo Pharma America, Inc.	phase 3	Dopamine agonist	Dopamine receptors (D1, D2)
Neupro	ROTIGOTINE	UCB	marketed	Nonergot Dopamine Agonist [EPC]	dopamine receptors	2007-01-01
DC	DC	Gary Archer Ph.D.	marketed	dopamine agonist	dopamine receptor
Rotigotine transdermal patch	Rotigotine transdermal patch	UCB BIOSCIENCES GmbH	marketed	Non-ergot dopamine agonist	Dopamine receptors (D1, D2, D3, D4, D5)
ROP+L-Dopa	ROP+L-Dopa	GlaxoSmithKline	marketed	Dopamine agonist + Levodopa combination	Dopamine receptors (D2/D3); Dopamine pathway
DAM	DAM	Beijing Bozhiyin T&S Co., Ltd.	marketed	Dopamine agonist	Dopamine receptor
amantadine sulfate	amantadine sulfate	Jee-Young Lee	marketed	Antiviral / Dopamine agonist	Influenza A M2 ion channel; dopamine system (mechanism not fully elucidated)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine agonist class)

Sumitomo Pharma America, Inc. · 2 drugs in this class
University Hospital, Toulouse · 2 drugs in this class
Rennes University Hospital · 2 drugs in this class
Britannia Pharmaceuticals Ltd. · 1 drug in this class
Desitin Arzneimittel GmbH · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Intec Pharma Ltd. · 1 drug in this class
Leiden University Medical Center · 1 drug in this class
Ludwig-Maximilians - University of Munich · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APL-130277 — Competitive Intelligence Brief. https://druglandscape.com/ci/apl-130277. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab